iRhythm Q2 FY26 net loss narrows to $0.4 million; revenue rises 20.1% to $224.2 million
IRTC•VitalConnect deal and updated outlook
iRhythm agreed to buy VitalConnect for about $287.5 million.
The company also raised its 2026 revenue outlook to $880 million-$890 million.
Q2 revenue growth and profitability improve
iRhythm posted Q2 2026 revenue of $224.2 million, up 20.1% from a year earlier.
GAAP net loss narrowed to $0.4 million, or $0.01 per diluted share.
Gross margin rose 1.6 percentage points to 72.8%.
Non-GAAP adjusted EBITDA climbed to $43.3 million, lifting margin to 19.3%.
